ClinicalTrials.gg
CompletedNCT03643380Updated Aug 22, 2018

Acute Study to Evaluate a Novel Implantable Midfield Powered Device in Humans With Urinary Incontinence

A Phase 1 interventional study of AHLeveeS System in Overactive Bladder, sponsored by Neuspera Medical, Inc.. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-08-22.

Sponsored by Neuspera Medical, Inc. · Phase 1, Interventional, and Device feasibility

How we know

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Aug 2017, registered Jul 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 43 studies in Urinary Bladder, Overactive with a site in Netherlands — none open to participants now, 1 under way, none of them phase 3. Urinary Bladder, Overactive · Netherlands.

Enrollment
34th of 36
6 · median 234
Started
2017
the only one that year
Phase 1
5 of 43
none open now
Registered
39th of 43
by date

Among the 43 studies in Urinary Bladder, Overactive with a site in Netherlands, this one is the 34th largest by enrollment of the 36 interventional ones that give a count, is the only one that started in 2017, is one of 5 in phase 1, and was the 39th registered.

Urinary Bladder, Overactive

861 studies on the registry are indexed under Urinary Bladder, Overactive; 128 are open to participants now.

Browse Urinary Bladder, Overactive studies →

Open to participants now

None of the 43 studies in Urinary Bladder, Overactive with a site in Netherlands is open now. The open studies under Urinary Bladder, Overactive, anywhere →

Who these studies take

Of the 75 Urinary Bladder, Overactive studies recruiting now, 45 (60%) set no upper age limit and 16 (21%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 43 studies in Urinary Bladder, Overactive with a site in Netherlands as a file.
02

Study summary

A pre-market, prospective, non-randomized acute feasibility study for the treatment of patients with urinary incontinence (UI) as a consequence of urinary incontinence.

03

Conditions studied

  • Overactive Bladder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject was eligible for treatment and indication for the Medtronic InterStim system or InterStim II
  • Subject wished to undergo an InterStim or InterStim II implant procedure after this acute clinical investigation
  • Subject was in good health in the opinion of the investigator
  • Subject was able to understand and voluntarily signed and dated the Ethics Committee approved form prior to initiation of any screening or study-specific procedures
  • Subject was minimum of 18 years and maximum of 65 years of age

Exclusion criteria

Exclusion Criteria:

  • Subject had any of the for the InterStim system or InterStim II system
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Investigational SNS device

    Device: AHLeveeS System

Interventions

  • DeviceAHLeveeS System

    AHLeveeS System for treatment of overactive bladder

06

What researchers measure

Primary outcomes

  1. Sacral Nerve Response measured by observed bellow response and big toe flexion

    Stimulation of the S3 sacral nerve measured by observed bellows response and big toe flexion

    Time frame: Procedure

  2. AHLeveeS System placement in the S3 foramen assessed by fluoroscopy image

    Confirm that the AHLeveeS System can be correctly placed and inserted in close proximity of the sacral nerve in the S3 foramina assessed by fluoroscopy image

    Time frame: Procedure

07

Study locations

1 site
  • Maastricht University
    Maastricht, 6202 AZ, Netherlands
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Nov 2017, 2 months.

Of 20 industry-sponsored phase 1 interventional studies under Urinary Bladder, Overactive, half reached primary completion within 6 months of starting (the median); a quarter within 4 and three quarters within 11. This study's 2 months is below that.

Counting every sponsor, half of 30 studies reached it within 9 months; a quarter within 4 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2018
First posted
Aug 22, 2018
StartActual
Aug 17, 2017
Primary completionActual
Nov 15, 2017
CompletionActual
Jan 30, 2018
Last update
Aug 22, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03643380
Lead sponsor
Neuspera Medical, Inc.
Responsible party
Sponsor
First posted
Aug 22, 2018
Start date
Aug 17, 2017
Primary completion
Nov 15, 2017
Completion
Jan 30, 2018
Last update
Aug 22, 2018

Study contacts

Gommert A. van Koeveringe
principal investigator · Maastricht University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion